Receptor tyrosine kinase inhibitors in thyroid cancer

被引：34

作者：

Castellone, Maria Domenica ^{[1
,2
]}

Carlomagno, Francesca ^{[1
,2
]}

Salvatore, Giuliana ^{[3
]}

Santoro, Massimo ^{[1
]}

机构：

[1] Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy

[2] CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy

[3] Univ Parthenope, Dipartimento Studi Ist & Sistemi Terr, I-80133 Naples, Italy

来源：

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM | 2008年 / 22卷 / 06期

关键词：

kinase; thyroid; monoclonal antibody; small-molecule inhibitor;

D O I：

10.1016/j.beem.2008.09.012

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

Thyroid cancer is frequently associated with the oncogenic conversion of receptor tyrosine kinases (RTKs) or their downstream signalling molecules. Hence, there is a strong biological rationale for assessing the efficacy of RTK blockade to treat patients who are resistant to or not candidates for treatment with radioactive iodine. The first results of clinical trials based on the use of RTK inhibitors in thyroid cancer patients have recently been published. Here we discuss targeting of specific RTKs as a potential therapeutic strategy for the treatment of thyroid cancer.

引用

页码：1023 / 1038

页数：16

共 100 条

[1]

Role of platelet-derived growth factors in physiology and medicine [J].

Andrae, Johanna ;

Gallini, Radiosa ;

Betsholtz, Christer .

GENES & DEVELOPMENT, 2008, 22 (10) :1276-1312

[2]

Mutational analysis of the tyrosine kinome in colorectal cancers [J].

Bardelli, A ;

Parsons, DW ;

Silliman, N ;

Ptak, J ;

Szabo, S ;

Saha, S ;

Markowitz, S ;

Willson, JKV ;

Parmigiani, G ;

Kinzler, KW ;

Vogelstein, B ;

Velculescu, VE .

SCIENCE, 2003, 300 (5621) :949-949

[3]

Targeting tyrosine kinases in cancer: The second wave [J].

Baselga, Jose .

SCIENCE, 2006, 312 (5777) :1175-1178

[4]

Modes of resistance to anti-angiogenic therapy [J].

Bergers, Gabriele ;

Hanahan, Douglas .

NATURE REVIEWS CANCER, 2008, 8 (08) :592-603

[5]

Pituitary tumor transforming gene and fibroblast growth factor-2 expression: Potential prognostic indicators in differentiated thyroid cancer [J].

Boelaert, K ;

McCabe, CJ ;

Tannahill, LA ;

Gittoes, NJL ;

Holder, RL ;

Watkinson, JC ;

Bradwell, AR ;

Sheppard, MC ;

Franklyn, JA .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (05) :2341-2347

[6]

Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features [J].

Bunone, G ;

Vigneri, P ;

Mariani, L ;

Butó, S ;

Collini, P ;

Pilotti, S ;

Pierotti, MA ;

Bongarzone, I .

AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (06) :1967-1976

[7]

Carlomagno F, 2002, CANCER RES, V62, P7284

[8]

BAY 43-9006 inhibition of oncogenic RET mutants [J].

Carlomagno, F ;

Anaganti, S ;

Guida, T ;

Salvatore, G ;

Troncone, G ;

Wilhelm, SM ;

Santoro, M .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (05) :326-334

[9]

Small molecule c-met inhibitor pha665752: Effect on cell growth and motility in papillary thyroid carcinoma [J].

Chattopadhyay, Chandrani ;

El-Naggar, Adel K. ;

Williams, Michelle D. ;

Clayman, Gary L. .

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2008, 30 (08) :991-1000

[10]

Drug therapy: EGFR antagonists in cancer treatment [J].

Ciardiello, Fortunato ;

Tortora, Giampaolo .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (11) :1160-1174

← 1 2 3 4 5 6 7 8 9 10 →